These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28733862)

  • 21. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.
    Krishna M; Nadler SG
    Front Immunol; 2016; 7():21. PubMed ID: 26870037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal.
    Garlits J; McAfee S; Taylor JA; Shum E; Yang Q; Nunez E; Kameron K; Fenech K; Rodriguez J; Torri A; Chen J; Sumner G; Partridge MA
    AAPS J; 2023 Apr; 25(3):37. PubMed ID: 37016171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical methods and tool for cut point analysis in immunogenicity assays.
    Zhang L; Zhang JJ; Kubiak RJ; Yang H
    J Immunol Methods; 2013 Mar; 389(1-2):79-87. PubMed ID: 23305975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statistical approaches for the determination of cut points in anti-drug antibody bioassays.
    Schaarschmidt F; Hofmann M; Jaki T; Grün B; Hothorn LA
    J Immunol Methods; 2015 Mar; 418():84-100. PubMed ID: 25733352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics.
    Kropshofer H; Singer T
    J Immunotoxicol; 2006 Sep; 3(3):131-6. PubMed ID: 18958693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A strategic approach to nonclinical immunogenicity assessment: a recommendation from the European Bioanalysis Forum.
    Laurén A; Goodman J; Blaes J; Cook J; Cowan KJ; Dahlbäck M; Grudzinska-Goebel J; McManus D; Nelson R; Pihl S; Timmerman P
    Bioanalysis; 2021 Apr; 13(7):537-549. PubMed ID: 33729007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size consideration for immunoassay screening cut-point determination.
    Zhang J; Zhang L; Yang H
    J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials.
    Carrasco-Triguero M; Dere RC; Milojic-Blair M; Saad OM; Nazzal D; Hong K; Kaur S
    Bioanalysis; 2019 Sep; 11(17):1555-1568. PubMed ID: 31208199
    [No Abstract]   [Full Text] [Related]  

  • 29. Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain.
    Johnson D; Simmons E; Abdeen S; Kinne A; Parmer E; Rinker S; Thystrup J; Ramaswamy S; Bowsher RR
    Sci Rep; 2021 Jul; 11(1):15467. PubMed ID: 34326436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1a.
    White JT; Crossman M; Richter K; Berman M; Goyal J; Subramanyam M
    Bioanalysis; 2015 Nov; 7(21):2801-11. PubMed ID: 26541956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Confirmatory cut point has limited ability to make accurate classifications in immunogenicity assays.
    Kubiak RJ; Arends RH; Lee N; Liang M; Zhang J; Roskos LK
    Bioanalysis; 2020 Feb; 12(4):245-256. PubMed ID: 32090586
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
    Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
    Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
    Ishii-Watabe A; Shibata H; Nishimura K; Hosogi J; Aoyama M; Nishimiya K; Saito Y
    Bioanalysis; 2018 Jan; 10(2):95-105. PubMed ID: 29243491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.
    Zhong ZD; Clements-Egan A; Gorovits B; Maia M; Sumner G; Theobald V; Wu Y; Rajadhyaksha M
    AAPS J; 2017 Nov; 19(6):1564-1575. PubMed ID: 29063411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.
    Liu Y; Reidler H; Pan J; Milunic D; Qin D; Chen D; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 64(3):238-45. PubMed ID: 21827863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Immunogenicity of Biologic Therapies.
    Garcês S; Demengeot J
    Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
    Pan J; Small T; Qin D; Li S; Wang L; Chen D; Pauley C; Verch T; Kaplanski C; Bakhtiar R; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 63(2):150-9. PubMed ID: 20868758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.